Commitments

12 Months Ended

Nov. 30, 2023

Disclosure of commitments [abstract]

26.	Commitments

(a)

Long-term

procurement agreements and research agreements

The Company has

long-term

procurement agreements with third party suppliers in connection with the commercialization of

EGRIFTA SV

and Trogarzo

. As at November 30, 2023, the Company had outstanding purchase orders and minimum payments required under these agreements amounting to $14,682

(2022

–

$1,644) for the manufacture of Trogarzo

EGRIFTA SV

and for other various services.

As at November 30, 202

, the Company also ha

research commitments and outstanding clinical material purchase orders amounting to $807 (2022 – $

1,310

) in connection with the oncology platform and nil

(2022

–

$868) in connection with a new formulation of tesamorelin and of a multi-dose pen injector developed for this new formulation.

(b)

Licence agreement

On February

, 2020, the Company entered into an amended and restated licence agreement with the Massachusetts General Hospital (“MGH”), as amended on April 15, 2020, in order to benefit from its assistance and knowledge for the development of tesamorelin for the potential treatment of

Non-Alcoholic

Steatohepatitis (“NASH”) in the general population. Under the terms of the amended agreement, the MGH, through Dr. Steven Grinspoon, will provide services related to the study design, selection of optimal patient population, dosing, study duration and other safety matters and participate, if need be, in regulatory meetings with the FDA or the EMA. In consideration, the Company agreed to make certain milestone payments to the MGH related to the development of tesamorelin and to pay a low single-digit royalty on all sales of

EGRIFTA

above a certain amount. The payment of the royalty will begin upon approval by the FDA or the EMA (the first to occur) of an expanded label of tesamorelin for the treatment of any fatty liver disease, including

Non-Alcoholic

Fatty Liver Disease or NASH in the general population.